JANUX THERAPEUTICS INC (JANX) Stock Price, Quote, News and Overview
NASDAQ:JANX - Nasdaq - US47103J1051 - Common Stock - Currency: USD
JANX Quote, Performance and Key Statistics
23.24
-0.11 (-0.47%)
The current stock price of JANX is 23.24 USD. In the past month the price decreased by -7.41%. In the past year, price decreased by -44.26%.
JANX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.05 | 327.47B | ||
| AMGN | AMGEN INC | 13.5 | 150.75B | ||
| GILD | GILEAD SCIENCES INC | 13.69 | 131.77B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.49B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.74 | 56.18B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.98B | ||
| ARGX | ARGENX SE - ADR | 97.48 | 34.23B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.83 | 28.90B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.19B | ||
| NTRA | NATERA INC | N/A | 22.42B | ||
| INSM | INSMED INC | N/A | 19.10B | ||
| BIIB | BIOGEN INC | 8.05 | 18.65B |
Related stock screener links
About JANX
Company Profile
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 74 full-time employees. The company went IPO on 2021-06-11. The company has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Company Info
JANUX THERAPEUTICS INC
10955 Vista Sorrento Parkway, Suite 200
San Diego CALIFORNIA US
CEO: David Campbell
Employees: 69
Phone: 18587514493
JANUX THERAPEUTICS INC / JANX FAQ
What is the stock price of JANUX THERAPEUTICS INC today?
The current stock price of JANX is 23.24 USD. The price decreased by -0.47% in the last trading session.
What is the ticker symbol for JANUX THERAPEUTICS INC stock?
The exchange symbol of JANUX THERAPEUTICS INC is JANX and it is listed on the Nasdaq exchange.
On which exchange is JANX stock listed?
JANX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for JANUX THERAPEUTICS INC stock?
19 analysts have analysed JANX and the average price target is 85.22 USD. This implies a price increase of 266.68% is expected in the next year compared to the current price of 23.24. Check the JANUX THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is JANUX THERAPEUTICS INC worth?
JANUX THERAPEUTICS INC (JANX) has a market capitalization of 1.38B USD. This makes JANX a Small Cap stock.
How many employees does JANUX THERAPEUTICS INC have?
JANUX THERAPEUTICS INC (JANX) currently has 69 employees.
What are the support and resistance levels for JANUX THERAPEUTICS INC (JANX) stock?
JANUX THERAPEUTICS INC (JANX) has a support level at 23.34 and a resistance level at 23.36. Check the full technical report for a detailed analysis of JANX support and resistance levels.
Is JANUX THERAPEUTICS INC (JANX) expected to grow?
The Revenue of JANUX THERAPEUTICS INC (JANX) is expected to decline by -95.98% in the next year. Check the estimates tab for more information on the JANX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy JANUX THERAPEUTICS INC (JANX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of JANX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of JANX, evaluating the profitability, health, valuation and growth aspects
- JANUX THERAPEUTICS INC (JANX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JANUX THERAPEUTICS INC (JANX) Sales and EPS estimates to see what analysts future expectations are.
- JANUX THERAPEUTICS INC (JANX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JANUX THERAPEUTICS INC (JANX) Insider and Institutional Ownership to learn about the owners and their transactions.
- JANUX THERAPEUTICS INC (JANX) Stock Chart to make your own analysis
- JANUX THERAPEUTICS INC (JANX) Latest news and press-releases to stay up to date.
Does JANUX THERAPEUTICS INC (JANX) stock pay dividends?
JANX does not pay a dividend.
When does JANUX THERAPEUTICS INC (JANX) report earnings?
JANUX THERAPEUTICS INC (JANX) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of JANUX THERAPEUTICS INC (JANX)?
JANUX THERAPEUTICS INC (JANX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).
What is the Short Interest ratio of JANUX THERAPEUTICS INC (JANX) stock?
The outstanding short interest for JANUX THERAPEUTICS INC (JANX) is 19.95% of its float. Check the ownership tab for more information on the JANX short interest.
JANX Technical Analysis
JANX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JANX. While JANX has a great health rating, there are worries on its profitability.
JANX Financial Highlights
Over the last trailing twelve months JANX reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by -11.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.4% | ||
| ROE | -7.68% | ||
| Debt/Equity | 0 |
JANX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to JANX. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of -59.52% and a revenue growth -95.98% for JANX